• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

CDK inhibitor E9

CAS No. 2020052-55-3

CDK inhibitor E9 ( E9 )

产品货号. M13145 CAS No. 2020052-55-3

CDK抑制剂E9是一种新型CDK抑制剂,可以克服ABC介导的THZ1耐药性,作为CDK9的有效非共价抑制剂和CDK12的共价抑制剂。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥2689 有现货
50MG ¥13365 有现货
100MG ¥20250 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    CDK inhibitor E9
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    CDK抑制剂E9是一种新型CDK抑制剂,可以克服ABC介导的THZ1耐药性,作为CDK9的有效非共价抑制剂和CDK12的共价抑制剂。
  • 产品描述
    CDK inhibitor E9 is a novel CDK inhibitor that can overcomes ABC-mediated resistance of THZ1, functions as a potent, non-covalent inhibitor of CDK9 and a covalent inhibitor of CDK12; does not serve as a substrate for either ABCB1 or ABCG2, while avoiding ABC transporter-mediated efflux; decreases the phosphorylated and total RNAPII in THZ1R NB and lung cancer cells (IC50=8-40 nM), accompanied by decreased MYC and MCL1 expression, exerts its cytotoxic effects through covalent modification of cysteine 1039 of CDK12.
  • 体外实验
    CDK12-IN-E9 (E9; 10 nM-10 μM; 72 hours; Kelly, LAN5, SK-N-BE2, PC-9, NCI-H82 and NCI-H3122 cells) treatment shows potent antiproliferative activity in THZ1R NB and lung cancer cells, with IC50 values ranging from 8 to 40 nM.CDK12-IN-E9 (E9; 0-3000 nM; 6 hours; Kelly, PC-9, and NCI-H82 cells) treatment leads to a dose-dependent decrease in phosphorylated and total RNAPII in THZ1r NB and lung cancer models, accompanied by decreased MYC and MCL1 expression.CDK12-IN-E9 also results in increased PARP cleavage, and an increase in the subGI population in THZ1r lung cancer cells, while in NB cells, more of a G2/M arrest is seen after a 24-hr exposure to CDK12-IN-E9. Cell Proliferation Assay Cell Line:Kelly, LAN5, SK-N-BE2, PC-9, NCI-H82 and NCI-H3122 cells Concentration:10 nM-10 μM Incubation Time:72 hours Result:Showed potent antiproliferative activity in THZ1R NB and lung cancer cells, with IC50 values ranging from 8 to 40 nM.Western Blot Analysis Cell Line:Kelly, PC-9, and NCI-H82 cells Concentration:0 nM, 30 nM, 100 nM, 300 nM, 1000 nM, 3000 nM Incubation Time:6 hours Result:Led to a dose-dependent decrease in phosphorylated and total RNAPII in THZ1r NB and lung cancer models.
  • 体内实验
    ——
  • 同义词
    E9
  • 通路
    Angiogenesis
  • 靶点
    CDK
  • 受体
    CDK
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    2020052-55-3
  • 分子量
    434.544
  • 分子式
    C24H30N6O2
  • 纯度
    >98% (HPLC)
  • 溶解度
    In Vitro:?DMSO : 125 mg/mL (287.67 mM)
  • SMILES
    C=CC(NC1=CC=CC(NC2=CC(N3[C@H](CCO)CCCC3)=NC4=C(CC)C=NN24)=C1)=O
  • 化学全称
    (S)-N-(3-((3-ethyl-5-(2-(2-hydroxyethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl)amino)phenyl)acrylamide

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Gao Y, et al. Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5.
产品手册
关联产品
  • PF07104091

    PF-07104091 抑制 CDK2,可能导致细胞周期停滞、诱导细胞凋亡并抑制肿瘤细胞增殖。

  • (R)-CR8

    (R)-CR8 是一种有效的选择性 CDK 抑制剂。CR8 是一种有效的第二代细胞周期蛋白依赖性激酶 (CDK) 抑制剂,LFP 后 3 小时延迟全身给药。

  • ML365

    ML365是一种新型选择性TASK1(KCNK3)小分子抑制剂。